Halozyme Therapeutics, Inc. (HALO): Cash & Equivalents
$133.82M
As of 2025-12-31
$163.14M
As of 2026-06-30
-17.0%
3-year compound annual growth
-2.0%
5-year compound annual growth
+11.9%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $133.82M | +15.5% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $115.85M | -2.1% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $118.37M | -49.5% | 2026-02-17, Balance as of period end |
| 2022-12-31 | $234.19M | +97.3% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $118.72M | -19.6% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $147.70M | +22.9% | 2022-02-22, Balance as of period end |
| 2019-12-31 | $120.18M | +107.4% | 2021-02-23, Balance as of period end |
| 2018-12-31 | $57.94M | -65.7% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $168.74M | +152.7% | 2019-02-21, Balance as of period end |
| 2016-12-31 | $66.76M | +54.2% | 2018-02-20, Balance as of period end |
| 2015-12-31 | $43.29M | -29.5% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $61.39M | +124.4% | 2017-02-28, Balance as of period end |
| 2013-12-31 | $27.36M | -72.5% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $99.50M | +90.0% | 2015-03-02, Balance as of period end |
| 2011-12-31 | $52.38M | -37.1% | 2014-02-28, Balance as of period end |
| 2010-12-31 | $83.26M | +23.4% | 2013-03-01, Balance as of period end |
| 2009-12-31 | $67.46M | n/a | 2012-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $839.00M | +26.4% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
Compare HALO, TECH, NVAX, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗